Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
Methods of regulating cannabinoid receptor activity-related disorders and diseases
US2016331702A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016331702-A1 |
| Application number | US-201615225643-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 1, 2016 |
| Priority date | May 25, 2012 |
| Publication date | Nov 17, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
First claim
Opening claim text (preview).
We claim: 1 . A method, comprising: inhibiting growth of cells regulated by CB receptor activity by exposing the cells to an effective amount of a compound having the formula wherein R 1 -R 3 are hydrogen; R 4 is lower alkyl; R 5 is…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/137Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016331702A1 cover?
- This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In o…
- Who is the assignee on this patent?
- Us Health
- What technology area does this patent fall under?
- Primary CPC classification A61K31/137. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Nov 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).